The CAMELIA randomized control trial conducted in Cambodia among 661 HIV-infected TB patients with a median CD4 count of 25 cells/mm3 found a 34% reduction in mortality associated with the early initiation of ART two weeks after onset of TB treatment, compared with eight weeks after onset [43]. This evidence concerns the gene CD4 and tuberculosis.